ADMA Stock Analysis: Buy, Sell, or Hold?
ADMA - ADMA Biologics, Inc.
$17.30
0.29 (1.70%)
▲
HOLD
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 02, 2026
29d
Smart Money Distribution
ADMA is up 3.4% this week, but smart money is buying puts. Top strike: $14 2026-03-20 with 3,377 OI. Put ratio: 76% View Scanner →
Strength: 4.3/10
Get Alerted When ADMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ADMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ADMA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$35.33
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$21.94
21.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ADMA is currently trading at $17.30, which is considered slightly low relative to its 30-day fair value range of $17.05 to $18.87. The stock's valuation (Forward PE: 18.1) is in line with its historical norms (19.3). Remarkably, the market is currently pricing in an annual earnings decline of 2.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $16.22, while resistance sits at $18.00.
Market Sentiment: ADMA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $25.67 (+50.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ADMA is in a strong downtrend. Immediate support is located at $16.22, while resistance sits at $18.00.
Market Sentiment: ADMA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $25.67 (+50.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$17.05 -
$18.87
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding ADMA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 50.9% below Wall St target ($25.67)
Fair Price Analysis
30-Day Fair Range
$17.05 -
$18.87
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$16.22
Resistance Level
$18.00
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
18.10
Wall Street Target
$25.67
(+50.9%)
Revenue Growth (YoY)
12.0%
Profit Margin
42.9%
Valuation Discount vs History
-2.2% cheaper
PE vs Historical
18.1 vs 19.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.2%
(market-implied from PE analysis)
1-Year Target
$16.64
(-2%)
2-Year Target
$16.27
(-4%)
3-Year Target
$15.91
(-7%)
3-Yr Target (if PE normalizes)
(PE: 18→19)
$16.97
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 56.7%)
$70.75
(+316%)
Base:
(SPY PE: 18.1, Growth: 56.7%)
$57.41
(+238%)
Bear:
(PE: 15.4, Growth: 56.7%)
$48.80
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 18.99 | Current EPS (TTM): $0.86
Bull Case
$19.63
(+14%)
Analyst growth 9.3%, PE expands to 20.9
Base Case
$17.85
(+3%)
Market implied 9.3%, PE stable at 19.0
Bear Case
$11.10
(-36%)
Severe decline -20.0%, PE contracts to 16.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.1 to 19.3
Stabilization Target:
$18.14
(+6.7%)
PE Expansion Potential:
+6.7%
Last updated: January 31, 2026 12:56 PM ET
Data refreshes hourly during market hours. Next update: 1:56 PM
Data refreshes hourly during market hours. Next update: 1:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ADMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$85 | 55 HOLD |
Advanced ADMA Option Strategies
Professional options setups generated by AI based on today's ADMA price and gamma walls.
